The FDA's Fast Track designation helps to accelerate the development and review of products for serious and life-threatening conditions.

Investigators compared clinical outcomes with docetaxel rechallenge vs cabazitaxel in patients with mCRPC who did not experience disease progression during prior administration of docetaxel for mCRPC.

In this retrospective study, researchers explored whether reducing osimertinib dose in EGFR-mutated metastatic NSCLC patients who experienced adverse events would worsen survival.

Experts are researching and exploring ways to standardize death and dying education across US medical schools. (HealthDay News) — There is considerable variation in how death and dying are taught in ...

BTK inhibitors (BTKi) in mantle cell lymphoma (MCL) are examined by Tycel J. Phillips, MD, particularly as potential first-line therapy.

In this study, researchers evaluated patients who had incomplete cCRT or experienced progression during or within 42 days of receiving cCRT, with an aim of identifying risk factors for these outcomes.

Investigators sought to determine the cost-effectiveness of home- versus clinic-based anal cancer screening for increasing uptake among sexual and gender minorities.

Dr Andrew Howard, chairman and president of the Kidney Transplant Collaborative, told the Associated Press that the drop off in kidney transplants would have been larger if not for a small increase of ...

Investigators sought to describe the patterns of post-progression outcome for patients with HR+/HER2- advanced breast cancer treated with endocrine therapy and a CDK4/6 inhibitor.

Investigators assessed the association between race, ethnicity and neighborhood-level SES with mortality among young adults with mCRC.

In treatment-naïve, unresectable HCC patients, nivolumab plus ipilimumab provides a sustained benefit compared to lenvatinib or sorafenib.

Investigators evaluated the association between risk-reducing bilateral mastectomy and overall and breast cancer–specific mortality in female carriers of BRCA pathogenic variants.